TYK2 and psoriasis: Deucravacitinib selectively binds to the regulatory domain of tyrosine kinase 2 (TYK2), an intracellular kinase that mediates signaling of interleukin-23 and other immune molecules implicated in the pathogenesis of psoriasis.2